Profile data is unavailable for this security.
About the company
Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.
- Revenue in GBP (TTM)0.00
- Net income in GBP-26.48m
- Incorporated2006
- Employees34.00
- LocationFaron Pharmaceuticals OyJoukahaisenkatu 6TURKU 20520FinlandFIN
- Phone+358 24695151Fax+358 24695152
- Websitehttps://www.faron.com/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
e-Therapeutics plc | 475.00k | -8.27m |
Poolbeg Pharma PLC | 0.00 | -3.93m |
Celadon Pharmaceuticals PLC | 20.74k | -8.06m |
Eco Animal Health Group Plc | 88.46m | -1.62m |
Scancell Holdings Plc | 0.00 | -11.32m |
Futura Medical PLC | 3.10m | -6.51m |
Faron Pharmaceuticals Oy | 0.00 | -26.48m |
Allergy Therapeutics plc | 53.26m | -50.22m |
4Basebio PLC | 354.00k | -6.28m |
Animalcare Group Plc | 74.35m | 1.20m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 31 Jan 2024 | 2.84m | 4.12% |
Fj�rde AP-fondenas of 31 Oct 2023 | 2.58m | 3.74% |
OP Asset Management Ltd.as of 31 Dec 2023 | 2.00m | 2.91% |
Sp-Fund Management Co. Ltd.as of 28 Mar 2024 | 800.04k | 1.16% |
Fondita Fund Management Co. Ltd.as of 31 Mar 2024 | 330.49k | 0.48% |
Canaccord Genuity Wealth Ltd.as of 30 Sep 2023 | 159.68k | 0.23% |
Danske Bank A/S (Investment Management Finland)as of 29 Feb 2024 | 140.77k | 0.21% |
Aktia Varainhoito Oyas of 31 Oct 2021 | 117.37k | 0.17% |
Janus Henderson Investors UK Ltd.as of 29 Feb 2024 | 100.00k | 0.15% |
BG Fund Management Luxembourg SAas of 30 Jun 2023 | 41.74k | 0.06% |